EXHIBIT A

Claims Chart Showing Descriptive Support in U.S. Provisional Patent Application Serial No. 60/441,391 for the claims of U.S. Patent Application Serial No. 10/542,501.

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	**Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003**
1. A method for treating bladder disease in a subject, said method comprising: administering intravesically to a subject a pharmaceutical composition comprising a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula  wherein Q is a group of the formula: $-CH_2-CH_2-$, $-CH=CH-$ or  R and R^1 are each independently C_1-C_4-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl and X^- is a physiologically acceptable anion; (2) a compound having the formula	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula  wherein Q is a group having the formula: $-CH_2-CH_2-$, $-CH=CH-$ or  R and R^1 are each independently C_1-C_4-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl and X^- is a physiologically acceptable anion; (page 6, lines 13-25; page 7, lines 1-2) (2) a compound having the formula:

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	**Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003**
	
wherein X^- is a physiologically acceptable ion;	wherein X^- is a physiologically acceptable ion; (page 7, lines 2-8)
(3) a compound having the formula 	(3) a compound having the formula 
wherein X^- is a physiologically acceptable ion;	wherein X^- is a physiologically acceptable ion; (page 7, lines 8-16)
(4) a compound having the formula 	(4) a compound having the formula 
wherein R_1 is 2-thienyl or cyclopentyl, and A is 3α-(6,7-dehydro)-tropanyl methobromide, 3β-tropanyl methobromide, or 3α-(N-isopropyl)-nortropanyl methobromide;	wherein R_1 is 2-thienyl or cyclopentyl, and A is 3α-(6,7-dehydro)-tropanyl methobromide, 3β-tropanyl methobromide, or 3α-(N-isopropyl)-nortropanyl methobromide; (page 7, lines 16-17; page 8, lines 1-7)

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	**Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003**
(5) a compound having the formula  wherein R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} alkyl group, or R and R^1 together form a C_{4-6} alkylene group; X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_2OH, C_{1-4} alkyl or C_{1-4} alkoxy;	(5) a compound having the formula  wherein R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} alkyl group, or R and R^1 together form a C_{4-6} alkylene group; X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_2OH, C_{1-4} alkyl or C_{1-4} alkoxy; (page 8, lines 7-15)
(6) a compound having the formula  wherein R is an optionally halo- or hydroxy-substituted C_{1-4} –alkyl group, R^1 is a C_{1-4} – alkyl group, or R and R^1 together form a C_{4-6}- alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_3, CH_2OH, C_{1-4} –alkyl, or C_{1-4} –alkoxy;	(6) a compound having the formula  wherein R is an optionally halo- or hydroxy-substituted C_{1-4} –alkyl group, R^1 is a C_{1-4} –alkyl group, or R and R^1 together form a C_{4-6}- alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_3, CH_2OH, C_{1-4} –alkyl, or C_{1-4} –alkoxy; (page 8, lines 15-20; page 9, lines 1-5)
(7) a compound having the formula  ;	(7) a compound having the formula  ; (page 9, lines 5-7)
(8) a compound having the formula	(8) a compound having the formula

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003
 ;	 ; (page 9, lines 5-7)
and (9) a compound having the formula 	and (9) a compound having the formula 
wherein X^- is a physiologically acceptable anion.	wherein X^- is a physiologically acceptable anion. (page 9, line 13; page 10, lines 1-5). Discloses that the preferred route of administration is intravesical (page 16, line 16)
2. The method according to claim 1, wherein the compound has the formula 	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of 
wherein Q is a group of the formula	wherein Q is a group of the formula

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	**Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003**
$-CH_2-CH_2-$, $-CH=CH-$ or  R and R^1 are each independently C_1-$_4$-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl, and X^- is a physiologically acceptable anion.	$-CH_2-CH_2-$, $-CH=CH-$ or  R and R^1 are each independently C_1-C_4-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl and X^- is a physiologically acceptable anion. (page 6, lines 13-25; page 7, lines 1-2)
3. The method according to claim 2, wherein R is CH_3, C_2H_5, n-C_3H_7, or i-C_3H_7 and R^1 is CH_3.	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of:  (page 6, lines 13-19) Discloses that R and R^1 are each independently C_1-C_4-alkyl; (page 7, lines 1-2) Discloses that examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl (page 20, lines 8-10).
4. The method according to claim 3, wherein R_1 is thienyl;	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of:  (page 6, lines 13-19)

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	**Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003**
	Discloses that R and R^1 are each independently C_1-C_4-alkyl; (page 7, lines 1-2) Discloses that R_1 is thienyl. (page 7, lines 1-2)
5. The method according to claim 2, wherein X^- is Br^- or CH_3SO_3	Discloses that pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compounds formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic. . . and salts prepared from organic acids such as . . . methanesulfonic … (page 20, lines 23-32)
6. The method according to claim 1, wherein the compound has the formula  wherein X^- is a physiologically acceptable ion.	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of:  wherein X^- is a physiologically acceptable ion. (page 6, lines 13-16; page 7, lines 3-8)
22. The method according to claim 1, wherein the compound has the formula	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	**Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16-2003**
 wherein X^- is a physiologically acceptable anion.	 wherein X^- is a physiologically acceptable anion. (page 9, line 13; page 10, lines 1-5).
23. The method according to claim 22, wherein X^- is a bromide.	Discloses that pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compounds formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic. . . (page 20, lines 23-27)
24. The method according to claim 1, wherein the pharmaceutical composition is formulated to have a prolonged duration of action.	Discloses that the pharmaceutical composition is formulated to have a prolonged duration of action. (page 19, lines 8-10)
25. The method according to claim 24, wherein the prolonged duration of action is at least about three weeks.	Discloses that the prolonged duration of action is at least about three weeks. (page 19, lines 14-17)
26. The method according to claim 1, wherein the pharmaceutical composition further comprises an additive selected from the group consisting of carboxymethyl celluloses, glycosaminoglycans, pentosan polysulfate, and heparin.	Discloses that the pharmaceutical composition further comprises an additive selected from the group consisting of carboxymethyl celluloses, glycosaminoglycans, pentosan polysulfate, and heparin. (page 16, lines 30-34; page 17, lines 1-3).
27. The method according to claim 1, wherein the subject has a condition selected from the group consisting of urge incontinence, cystitis, bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele, spinal cord injury, dementia where antimuscarinic medications are contraindicated, parkinsonism, and inability to tolerate systemic effects of antimuscarinic medications.	Discloses that the subject has a condition selected from the group consisting of urge incontinence, cystitis, bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele, spinal cord injury, dementia where antimuscarinic medications are contraindicated, parkinsonism, and inability to tolerate systemic effects of antimuscarinic medications. (page 16, lines 19-29)